(4-Cyclohexylfuran-2-yl)methanol | 183163-84-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 杂芳族化合物
• 英文名称: (4-Cyclohexylfuran-2-yl)methanol
• 英文别名: (4-cyclohexylfuran-2-yl)methanol
• CAS: 183163-84-0
• 化学式: C₁₁H₁₆O₂
• 分子量: 180.247
• InChiKey: VQTRKGWUWWLYGX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  33.4
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (4-Cyclohexylfuran-2-yl)methanol 在 magnesium sulfate 、 戴斯-马丁氧化剂 、 三乙胺 作用下， 以 乙醚 、 二氯甲烷 为溶剂， 反应 51.0h， 生成 (1R)-1-(4-cyclohexylfuran-2-yl)propan-1-amine
  参考文献：
  名称：

  C(4)-alkyl substituted furanyl cyclobutenediones as potent, orally bioavailable CXCR2 and CXCR1 receptor antagonists

  摘要：

  A novel series of cyclobutenedione centered C(4)-alkyl substituted furanyl analogs was developed as potent CXCR2 and CXCR1 antagonists. Compound 16 exhibits potent inhibitory activities against IL-8 binding to the receptors (CXCR2 Ki = 1 nM, IC50 = 1.3 nM; CXCRI Ki = 3 nM, IC50= 7.3 nM), and demonstrates potent inhibition against both Gro-alpha and IL-8 induced hPMN migration (chemotaxis: CXCR2 IC50=0.5nM,CXCRI IC50= 37 nN1). In addition, 16 has shown good oral pharmacokinetic profiles in rat, mouse, monkey, and dog. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.04.016
• 作为产物：
  描述：

  5-硝基-2-糠酸甲酯 在 lithium aluminium tetrahydride 、 偶氮二异丁腈 、 potassium tert-butylate 、 三正丁基氢锡 作用下， 以 四氢呋喃 、 六甲基磷酰三胺 、 甲苯 为溶剂， 反应 7.0h， 生成 (4-Cyclohexylfuran-2-yl)methanol
  参考文献：
  名称：

  C(4)-alkyl substituted furanyl cyclobutenediones as potent, orally bioavailable CXCR2 and CXCR1 receptor antagonists

  摘要：

  A novel series of cyclobutenedione centered C(4)-alkyl substituted furanyl analogs was developed as potent CXCR2 and CXCR1 antagonists. Compound 16 exhibits potent inhibitory activities against IL-8 binding to the receptors (CXCR2 Ki = 1 nM, IC50 = 1.3 nM; CXCRI Ki = 3 nM, IC50= 7.3 nM), and demonstrates potent inhibition against both Gro-alpha and IL-8 induced hPMN migration (chemotaxis: CXCR2 IC50=0.5nM,CXCRI IC50= 37 nN1). In addition, 16 has shown good oral pharmacokinetic profiles in rat, mouse, monkey, and dog. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.04.016

文献信息

• A novel route to 2-fluoromethyl- and 2-hydroxymethyl-4-alkyl furans via allene oxides
  作者：Marek M. Kabat

  DOI：10.1016/0040-4039(96)01605-x

  日期：1996.10

  A four-step protocol for the synthesis of 2-fluoromethyl and 2-hydroxymethyl 4-alkyl furans 1a and 1b from a-alkyl acroleins 4 and 1-bromo-1-trimethylsilylethylene (5) via allene oxides 2 is elaborated, and is applied to the preparation of steroid furans 10, 11, 14 and 15 from alpha,beta-unsaturated aldehyde 8. Copyright (C) 1996 Published by Elsevier Science Ltd
• C(4)-alkyl substituted furanyl cyclobutenediones as potent, orally bioavailable CXCR2 and CXCR1 receptor antagonists
  作者：Jianhua Chao、Arthur G. Taveras、Jianping Chao、Cynthia Aki、Michael Dwyer、Younong Yu、Biju Purakkattle、Diane Rindgen、James Jakway、William Hipkin、James Fosetta、Xuedong Fan、Daniel Lundell、Jay Fine、Michael Minnicozzi、Jonathan Phillips、J. Robert Merritt

  DOI：10.1016/j.bmcl.2007.04.016

  日期：2007.7

  A novel series of cyclobutenedione centered C(4)-alkyl substituted furanyl analogs was developed as potent CXCR2 and CXCR1 antagonists. Compound 16 exhibits potent inhibitory activities against IL-8 binding to the receptors (CXCR2 Ki = 1 nM, IC50 = 1.3 nM; CXCRI Ki = 3 nM, IC50= 7.3 nM), and demonstrates potent inhibition against both Gro-alpha and IL-8 induced hPMN migration (chemotaxis: CXCR2 IC50=0.5nM,CXCRI IC50= 37 nN1). In addition, 16 has shown good oral pharmacokinetic profiles in rat, mouse, monkey, and dog. (c) 2007 Elsevier Ltd. All rights reserved.